| Entry |
|
|---|
| Name |
Amifampridine phosphate (USAN);
Firdapse (TN) |
|---|
| Product |
|
|---|
| Formula |
C5H7N3. H3PO4
|
|---|
| Exact mass |
207.0409
|
|---|
| Mol weight |
207.1244
|
|---|
| Structure |
|
|---|
| Remark |
| Product (DG02003): | D10228<US> D10689<US> |
|
|---|
| Efficacy |
Autoimmune disease treatment, Potassium channel blocker |
|---|
| Disease |
Lambert-Eaton myasthenic syndrome [DS: H01596] |
|---|
| Comment |
Treatment of Lambert-Eaton myasthenic syndrome (LEMS)
|
|---|
| Target |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N07 OTHER NERVOUS SYSTEM DRUGS
N07X OTHER NERVOUS SYSTEM DRUGS
N07XX Other nervous system drugs
N07XX05 Amifampridine
D10689 Amifampridine phosphate (USAN) <US>
USP drug classification [BR:br08302]
Central Nervous System Agents
Central Nervous System, Other
Amifampridine
D10689 Amifampridine phosphate (USAN)
Target-based classification of drugs [BR:br08310]
Ion channels
Voltage-gated ion channels
Potassium channels
KCNA
D10689 Amifampridine phosphate (USAN) <US>
KCNB
D10689 Amifampridine phosphate (USAN) <US>
KCNC
D10689 Amifampridine phosphate (USAN) <US>
KCND
D10689 Amifampridine phosphate (USAN) <US>
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10689
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 13
1 C8y C 20.3700 -16.7300
2 C8x C 20.3700 -18.1300
3 N5x N 21.5600 -18.8300
4 C8x C 22.8200 -18.1300
5 C8x C 22.8200 -16.7300
6 C8y C 21.5600 -16.0300
7 N1a N 21.5600 -14.6300
8 N1a N 19.1800 -16.0300
9 P1b P 26.4600 -17.6400
10 O1c O 26.4600 -16.2400
11 O1c O 27.8600 -17.6400
12 O1c O 25.0600 -17.6400
13 O1c O 26.4600 -19.0400
BOND 12
1 1 2 2
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 2
6 1 6 1
7 6 7 1
8 1 8 1
9 9 10 2
10 9 11 1
11 9 12 1
12 9 13 1
|
|---|
